Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults (Q36548076)

14 August 2017

1 reference

title

Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults (English)

1 reference

14 August 2017

anti-retroviral agent

0 references

Francesca Cainelli

2

0 references

Sandro Vento

object named as

Sandro Vento

5

0 references

author name string

Zelalem Temesgen

1

1 reference

PubMed ID

16870528

14 August 2017

Eric M Poeschla

3

1 reference

PubMed ID

16870528

14 August 2017

Stacey A R Vlahakis

4

1 reference

14 August 2017

1 August 2006

1 reference

Lancet Infectious Diseases

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

8

1 reference

14 August 2017

496-507

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Decline in deaths from AIDS due to new antiretrovirals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

The prevalence of antiretroviral drug resistance in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precur

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

HIV-1 pol replication capacity predicts disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Implications of antiretroviral resistance on viral fitness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Principles and practice of HIV-protease inhibitor pharmacoenhancement

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Therapeutic drug monitoring as a tool in treating HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Predictors of virological response to atazanavir in protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970550-3

7 January 2021

10.1016/S1473-3099(06)70550-3

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16870528